GlassScriptPhysician profile
David W Barnett
NPI 1245251743
$1,710.80
in general payments reported to CMS, 2019-2025
23 companies · $40.31 in 2025
The $40.31 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.62 · 2020: $39.27 · 2021: $74.53 · 2022: $347 · 2023: $334 · 2024: $839 · 2025: $40.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $340.66 | 2019-2025 | Vivigen Mis Delivery System, Conduit, Matrix |
| Argenx US, INC. | $314.12 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $229.14 | 2023-2024 | Emgality, Reyvow, Kisunla |
| Eisai INC. | $107.89 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $104.53 | 2022 | |
| Merz Pharmaceuticals, LLC | $100.67 | 2021-2024 | Xeomin |
| Janssen Pharmaceuticals, INC | $99.86 | 2022 | |
| Lundbeck LLC | $89.55 | 2022-2024 | Vyepti |
| Abbvie INC. | $42.26 | 2023-2024 | Qulipta |
| Ucb, INC. | $39.75 | 2024 | Rystiggo |
| Sk Life Science, INC. | $26.44 | 2024 | |
| Amneal Pharmaceuticals LLC | $24.31 | 2023 | Rytary |
| Teva Pharmaceuticals USA, INC. | $23.43 | 2022 | |
| Genentech USA, INC. | $22.68 | 2023 | Enspryng, Ocrevus |
| Neurelis, INC. | $21.71 | 2023 | Valtoco |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $19.87 | 2023 | Gamunex-C |
| Ethicon US, LLC | $17.06 | 2019 | |
| Amgen INC. | $15.65 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.19 | 2023 | Nuedexta |
| Avadel Cns Pharmaceuticals, LLC | $15.06 | 2024 | Lumryz |
| Tg Therapeutics, INC. | $14.46 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.48 | 2022 | |
| Banner Life Sciences, LLC | $13.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.